Dr. John E. Kelly III, IBM Senior Vice President, Cognitive Solutions and IBM Research, says they have a lot to be proud of, including their pioneering work with IBM Watson Health. Unfortunately, some media reports, including an August 11th story published by The Wall Street Journal, distort and ignore facts when suggesting IBM has not made “enough” progress on bringing the benefits of AI to healthcare. Dr .Kelly feels it is imperative to set the record straight.
It is true, as the article reports, that IBM have placed a big bet on healthcare. We have done this for two reasons: 1) Most importantly, we know that AI can make a big difference in solving medical challenges and supporting the work of the healthcare industry, and 2) We see an enormous business opportunity in this area as the adoption of AI increases.
Our focus at IBM Watson Health is in applying next-generation AI technology to cancer care and other major healthcare challenges so people around the world can live better, healthier, longer lives.
We have built three distinct cancer tools that help physicians around the world treat patients:
- Watson for Oncology provides treatment options that augment an oncologists’ own expertise
- Watson for Clinical Trial Matching helps match patients with potentially life-saving clinical trials, and
- Watson for Genomics uses genetic sequencing to make strides towards personalized oncology.
We are working closely with premier cancer institutes like Memorial Sloan Kettering and Mayo Clinic to evolve and refine these tools. Together they are now in use at 230 hospitals and health organizations globally and have nearly doubled the number of patients they’ve reached in the first six months of the year to 84,000.
We have always believed that the role of technology is to assist a doctor in delivering better care and patient outcomes. Therefore, the first question we asked ourselves was, “can Watson help oncologists make better decisions for their patients?” Repeatedly, the answer has proven to be a resounding “yes,” as demonstrated in both peer-reviewed research as well as regular feedback from those using these tools.
To suggest there has been no patient benefit is to ignore both what we know The Wall Street Journal was told by a number of physicians around the world and these institutions’ own public comments—which we believe speak for themselves.
Dr. Michael Kelley and the Department of Veterans Affairs just extended their contract with us for Watson for Genomics, with nearly 3,000 veterans facing Stage 4 cancer being supported by this tool so far.
Dr. William Kim and the University of North Carolina Lineberger Cancer Center published a study where Watson for Genomics found new, actionable mutations in 32% of patients.
IBM has never shied away from grand challenges, and we know they don’t happen overnight and are not easy. Whether it’s the creation of the world’s first commercial computer, putting man on the moon, or more recently developing the fastest and smartest supercomputer on the planet, we go all in.
